Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
about
Translation of genomics and epigenomics in prostate cancer: progress and promising directionsRole of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?Non-invasive actionable biomarkers for metastatic prostate cancer.Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.Emerging biomarkers in the diagnosis of prostate cancer.
P2860
Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Development of AR-V7 as a puta ...... ion-resistant prostate cancer.
@en
type
label
Development of AR-V7 as a puta ...... ion-resistant prostate cancer.
@en
prefLabel
Development of AR-V7 as a puta ...... ion-resistant prostate cancer.
@en
P2860
P921
P356
P1476
Development of AR-V7 as a puta ...... ion-resistant prostate cancer.
@en
P2093
P2860
P304
P356
10.4103/1008-682X.178490
P5008
P577
2016-05-13T00:00:00Z